Netupitant 100 mg | 99.95%
TargetMol
Netupitant is a specific neurokinin 1 (NK1) receptor antagonist (Ki: 0.95 nM).
More Information Supplier PageNetupitant
Search Results
Rasagiline Mesylate 200 mg | Purity Not Available
TargetMol
Rasagiline Mesylate (AGN1135) is a novel MAO-B inhibitor, which can treat idiopathic Parkinson’s disease.
More Information Supplier PageRasagiline Mesylate
Resiquimod 25 mg | 99.81%
TargetMol
Resiquimod is an imidazoquinoline amine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of […]
More Information Supplier PageResiquimod
Resiquimod 100 mg | 99.81%
TargetMol
Resiquimod is an imidazoquinoline amine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of […]
More Information Supplier PageResiquimod
Voxtalisib 50 mg | 99.36%
TargetMol
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
More Information Supplier PageVoxtalisib
Voxtalisib 10 mg | 99.36%
TargetMol
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
More Information Supplier PageVoxtalisib
Voxtalisib 2 mg | 99.36%
TargetMol
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
More Information Supplier PageVoxtalisib
Ulixertinib 50 mg | 99.89%
TargetMol
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
More Information Supplier PageUlixertinib
Ulixertinib 10 mg | 99.89%
TargetMol
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
More Information Supplier PageUlixertinib
Ulixertinib 2 mg | 99.89%
TargetMol
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
More Information Supplier PageUlixertinib